Recombinant varicella zoster virus glycoprotein e antigen for myocardial infarction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Mar 2026: Trial registered, NCT07485283
  2. 28 Apr 2026: Trial started, NCT07485283

The trials

NCT07485283: Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia

State
Under way
Phase
Phase 4
People
168,460 taking part
Started
28 Apr 2026
Primary completion
Jun 2029
Arms
Recombinant Herpes Zoster Vaccine (Shingrix).
Results
None posted
  1. 20 Mar 2026: Trial registered
  2. 28 Apr 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as RZV vaccine, Recombinant Herpes Zoster Vaccine (Shingrix), Recombinant zoster vaccine, Shingrix.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.